196 related articles for article (PubMed ID: 35620187)
1. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
[TBL] [Abstract][Full Text] [Related]
5. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.
Kayali S; Pasta A; Plaz Torres MC; Jaffe A; Strazzabosco M; Marenco S; Giannini EG
Liver Int; 2023 Jan; 43(1):8-17. PubMed ID: 36102312
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation.
Saleh Y; Abu Hejleh T; Abdelrahim M; Shamseddine A; Chehade L; Alawabdeh T; Mohamad I; Sammour M; Turfa R
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893200
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.
Guo Z; Liu Y; Ling Q; Xu L; Wang T; Zhu J; Lin Y; Lu X; Qu W; Zhang F; Zhu Z; Zhang J; Jia Z; Zeng P; Wang W; Sun Q; Luo Q; Hu Z; Zheng Z; Jia Y; Li J; Zheng Y; Wang M; Wang S; Han Z; Yu S; Li C; Zhang S; Xiong J; Deng F; Liu Y; Chen H; Wang Y; Li L; Liang W; Schlegel A; Nashan B; Liu C; Zheng S; He X
Am J Transplant; 2024 Apr; ():. PubMed ID: 38642712
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
Yang PC; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH
World J Hepatol; 2016 Nov; 8(31):1309-1317. PubMed ID: 27872682
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.
Luo Y; Teng F; Fu H; Ding GS
World J Gastrointest Oncol; 2022 Jan; 14(1):163-180. PubMed ID: 35116109
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
16. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation.
Pelizzaro F; Gambato M; Gringeri E; Vitale A; Cillo U; Farinati F; Burra P; Russo FP
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638365
[TBL] [Abstract][Full Text] [Related]
17. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
18. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
Anugwom CM; Leventhal TM; Debes JD
Hepatoma Res; 2022; 8():. PubMed ID: 35693455
[TBL] [Abstract][Full Text] [Related]
19. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.
Wang LY; Zheng SS
J Zhejiang Univ Sci B; 2018 Jul; 19(7):497-504. PubMed ID: 29971988
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
